| Market Cap | 5.39M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -7.02M | Forward P/E | 2.35 | EPS next Y | - | 50D Avg Chg | -82.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -50.00% |
| Dividend | N/A | Price/Book | 2.30 | EPS next 5Y | - | 52W High Chg | -98.00% |
| Recommedations | 2.00 | Quick Ratio | 2.09 | Shares Outstanding | 13.48M | 52W Low Chg | 95.00% |
| Insider Own | 23.42% | ROA | -69.35% | Shares Float | 8.57M | Beta | -1.15 |
| Inst Own | 13.28% | ROE | -172.16% | Shares Shorted/Prior | 90.70K/1.13M | Price | 0.40 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 7,283,975 | Target Price | 12.00 |
| Oper. Margin | - | Earnings Date | Jul 26 | Volume | 1,113,467 | Change | -13.04% |
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.